经济观察网 基于公开信息，东阳光药（06887.HK）在2026年及近期有以下值得关注的事件动态，主要 涉及产品获批、研发进展及市场格局变化。以下内容整理自公开资料，事件时间线以最新公告为准。 近期受关注事件 仿制药市场准入与专利到期 富马酸伏诺拉生片（原研为武田制药的P-CAB药物）于2026年1月30日获批仿制并视同通过一致性评 价，为2026年8月29日专利到期后的市场放量做准备。目前国内已有39家企业获批该品种，专利到期后 可能面临价格竞争。 原研药份额在专利到期后可能快速下滑，仿制药价格下行压力凸显，市场对东阳光药长期盈利能力存在 分歧。 甘精胰岛素在美国市场的BLA批准预计在2026年上半年完成，门冬胰岛素也计划于2026年底获批，助力 国际化布局。 2026年1月，SGLT-2抑制剂奥洛格列淨胶囊获批上市，并与晶泰科技合作AI药物研发平台，形成短期催 化。 业务与技术发展 技术平台与战略合作 公司于2026年1月推出面向PROTAC机制的AI智能研发平台，整合临床管线数据，首个AI驱动小分子药 物HEC169584已进入临床I期。 通过海外BD合作加速国际化，如2024年11月与英国Apollo ...

Company Overview - Dongyang Sunshine Pharmaceutical (东阳光药) received approval for Fumaric Acid Vonoprazan Tablets on January 30, 2026, leading to stock price fluctuations influenced by product approval and market expectations regarding competition and profitability [1] - The company's core product, Oseltamivir Phosphate (可威), is expected to account for over 60% of revenue in the first half of 2025, but is projected to decline by 37.1% in 2024 due to procurement issues [4] Industry Analysis - The generic drug market is highly competitive, with 39 companies already approved for the same product and an additional 69 companies under review, indicating potential price wars and profit margin compression post-patent expiration [3] - Takeda Pharmaceutical currently holds a monopoly in the market, but its market share is expected to decline rapidly after the patent protection period ends on August 29, 2026, leading to downward pressure on generic drug prices [3] Financial Performance - The company's price-to-earnings ratio (TTM) is negative at -57.55, reflecting ongoing profitability challenges [4] - On February 12, during a stock price drop, trading volume surged to 20.49 million HKD, indicating increased market volatility and diverging opinions among investors [4] Market Trends - The biopharmaceutical sector has seen a decline, with the A-share biopharmaceutical index dropping by 3.52% over the past 20 days, while the Hong Kong Hang Seng Index fell by 1.72%, suggesting weak industry sentiment [5] - Over the last 20 trading days, southbound funds have seen a net reduction of 38,060 shares, indicating short-term pressure on capital [6]

Core Viewpoint - Guangdong Dongyangguang Pharmaceutical Co., Ltd. is seeking to go public in Hong Kong through a listing by introduction, leveraging its leading position in the flu drug Oseltamivir [1][2] Group 1: Company Overview - Dongyangguang Pharmaceutical is a comprehensive pharmaceutical company focused on the research, production, and commercialization of drugs, particularly in the fields of infections, chronic diseases, and oncology [2] - The company has 48 drug products sold in the domestic market and 23 in overseas markets as of June 2025 [2] Group 2: Financial Performance - Sales revenue from anti-infection drugs for 2022, 2023, and 2024 were 3.243 billion, 5.746 billion, and 2.798 billion yuan, accounting for 85%, 90%, and 69.6% of total revenue respectively [2] - Sales revenue from chronic disease treatments for the same years were 517 million, 581 million, and 1.068 billion yuan, representing 13.6%, 9.1%, and 26.6% of total revenue respectively [2] - Oseltamivir sales accounted for 81.2%, 86.9%, and 64.2% of total revenue in 2022, 2023, and 2024, with a market share of 54.8% in 2024 [2][3] Group 3: Strategic Moves - The company plans to privatize its subsidiary Dongyangguang Changjiang Pharmaceutical through a merger, which will not involve new stock issuance or fundraising [4] - This merger aims to enhance the company's position as a comprehensive pharmaceutical entity, integrate sales channels, and improve operational efficiency [4] Group 4: Industry Trends - There is a resurgence in the trend of innovative drug companies seeking IPOs in Hong Kong, with seven companies, including Dongyangguang Pharmaceutical, having submitted applications since June [5] - The Hong Kong Stock Exchange's 2018 reform allows unprofitable biotech companies to list, providing crucial funding avenues for R&D-intensive firms [6]